Piha-Paul, Sarina A. http://orcid.org/0000-0001-9455-1660
Thein, Kyaw Z.
De Souza, Paul
Kefford, Richard
Gangadhar, Tara
Smith, Christopher
Schuster, Shelly
Zamboni, William C.
Dees, Claire E.
Markman, Ben
Article History
Received: 16 December 2020
Accepted: 1 February 2021
First Online: 16 February 2021
Declarations
: The study protocol was approved by the Institutional Review Board or Independent Ethics Committee at each participating site and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice, and all local and federal regulatory guidelines. All patients signed informed consent prior to enrolling onto the study.
: None of the authors have any conflict of interest relevant to the subject of this manuscript.<b>Sarina A. Piha-Paul</b> receives Research/Grant Funding through the institution from the following sources: AbbVie, Inc.; ABM Therapeutics, Inc.; Acepodia, Inc; Alkermes; Aminex Therapeutics; Amphivena Therapeutics, Inc.; BioMarin Pharmaceutical, Inc; Boehringer Ingelheim; Bristol Myers Squib; Cerulean Pharma, Inc.; Chugai Pharmaceutical Co., Ltd; Curis, Inc.; Daiichi Sankyo; Eli Lilly; ENB Therapeutics; Five Prime Therapeutics; Gene Quantum; Genmab A/S; GlaxoSmithKline; Helix BioPharma Corp.; Incyte Corp.; Jacobio Pharmaceuticals Co., Ltd.; Medimmune, LLC.; Medivation, Inc.; Merck Sharp and Dohme Corp.; Novartis Pharmaceuticals; Pieris Pharmaceuticals, Inc.; Pfizer; Principia Biopharma, Inc.; Puma Biotechnology, Inc.; Rapt Therapeutics, Inc.; Seattle Genetics; Silverback Therapeutics; Taiho Oncology; Tesaro, Inc.; TransThera Bio; NCI/NIH; P30CA016672 – Core Grant (CCSG Shared Resources).<b>Paul De Souza</b> receives funding through his institution as a consultant for BioSceptre.<b>Tara Gangadhar</b> receives honoraria for scientific advisory board participation from Merck, and BMS.<b>Christopher Smith</b> and <b>Shelly Schuster</b> were employees of and held stock in NewLink Genetics Corporation.<b>William C. Zamboni</b> receives research funding from: Apollomics (formally CBT Pharma); Meryx Pharma; OBI Pharma; ChemoGLO, LLC; Glolytics, LLC; Nemucore, Inc; NexImmune; ZY Therapeutics; Merrimack Pharma; Genentech. <b>Has worked or is working as a consultant</b>: Cerulean Pharma; BlueLink Pharmaceuticals; Ellipses Pharma; Syros Pharmaceuticals; OBI Pharmaceuticals; Akagera Medicines; Merrimack Pharmaceuticals. <b>Additional positions held</b>: CEO, MediGLO - Medical and Pharmaceutical Consulting, LLC; CSO, ChemoGLO, LLC; CSO, Glolytics, LLC.All remaining authors have declared no conflicts of interest.